Peptide / Sexual Health

PT-141 (Bremelanotide)

FDA-approved (Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Central CNS mechanism — not vascular like PDE5 inhibitors. Inject 45 min before activity.

Build protocol outline Open dose calculator TNHL ebooks

Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.

Reference dose1–2 mg SubQ 45 minutes prior to activity

Half-life2.7 hours

Risk flagmoderate

Regulatory noteFDA-approved context noted

Side effects and watch-outs

Nausea (very common — pre-dose ondansetron 4 mg widely used)
Vomiting
Flushing
Headache
Transient blood pressure increase
Hyperpigmentation with frequent use
⚠️ Contraindicated in uncontrolled hypertension or CVD
Injection site bruising